Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 15/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296899 | 0.74 | MAPK1 (0.42) | NOTUM | |
| SCHEMBL184324 | 0.73 | NOTUM (0.52) | NOTUM | |
| SCHEMBL17028448 | 0.73 | NOTUM (0.41) | NOTUMKEAP1CYP19A1CYP1A2CYP2C9 | |
| SCHEMBL17007253 | 0.70 | NOTUM (0.55) | NOTUMKEAP1CYP19A1CYP1A2CYP2C9 | |
| SCHEMBL1196793 | 0.70 | NOTUM (0.55) | NOTUMKEAP1CYP19A1CYP1A2CYP2C9 | |
| SCHEMBL1195718 | 0.70 | NOTUM (0.55) | NOTUMKEAP1CYP19A1CYP1A2CYP2C9 | |
| SCHEMBL1586262 | 0.69 | NOTUM (0.44) | NOTUMKEAP1CYP19A1CYP1A2CYP2C9 | |
| SCHEMBL1586846 | 0.69 | NOTUM (0.44) | NOTUMKEAP1CYP19A1 | |
| SCHEMBL28508016 | 0.69 | NOTUM (0.44) | NOTUMKEAP1CYP19A1CYP1A2CYP2C9 | |
| SCHEMBL75570 | 0.69 | NOTUM (0.63) | NOTUMKEAP1CYP19A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48841-E1 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-07 | — | — | US | claimed |
| CN-113164458-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | claimed |
| US-11059828-B2 | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-07-13 | — | — | US | claimed |
| EP-3107898-B1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-01-06 | — | — | EP | claimed |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-23 | — | — | US | claimed |
| US-20200048263-A1 | Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-13 | — | — | US | claimed |
| EP-3093291-B1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-08 | — | — | EP | claimed |
| US-20180282309-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | US | claimed |
| EP-3371151-A1 | COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS | Agency For Science, Technology And Research (SG) | 2018-09-12 | — | — | EP | claimed |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-03 | — | — | US | claimed |
| EP-2491038-A1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C]PYRROLES AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2012-08-29 | — | — | EP | claimed |
| US-20120208812-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-08-16 | — | — | US | claimed |
| WO-2011050198-A1 | DISUBSTITUTED OCTAHY - DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | claimed |
| US-5866583-A | Substituted 2,4-diaminopyrimidines | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | claimed |
| EP-0023026-B1 | MIXTURES OF OPTICAL BRIGHTENERS AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1984-02-22 | — | — | EP | claimed |
| EP-0023028-B1 | MIXTURES OF OPTICAL BRIGHTENERS AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-12-15 | — | — | EP | claimed |
| US-4336155-A | CYANOSTYRYL COMPOUNDS AND OTHER BRIGHTENER | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-06-22 | — | — | US | claimed |
| US-4330427-A | Mixtures of optical brighteners | HOECHST AKTIENGESELLSCHAFT (DE) | 1982-05-18 | — | — | US | claimed |
| EP-0023026-A1 | Mixtures of optical brighteners and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-01-28 | — | — | EP | claimed |
| EP-0023028-A1 | Mixtures of optical brighteners and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-01-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282309-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | NOTUM 4479/4885KEAP1 702/4885CYP19A1 447/4885 |
| US-20120208812-A1 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OXTR | NOTUM 3681/4885KEAP1 2381/4885CYP19A1 2524/4885 |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | NOTUM 4545/4885KEAP1 698/4885CYP19A1 466/4885 |
| US-20200048263-A1 | Disubstituted Octahydropyrrolo[3,4-C]Pyrroles As Orexin Receptor Modulators | HCRTR2, HCRTR1, OXTR | NOTUM 3681/4885KEAP1 2381/4885CYP19A1 2524/4885 |
| US-11059828-B2 | Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | NOTUM 3681/4885KEAP1 2381/4885CYP19A1 2524/4885 |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | NOTUM 4479/4885KEAP1 702/4885CYP19A1 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.